-

01:07:57 PM

RVMD Stock News

RVMD - Revolution Medicines Inc

09/19/23 7:00 AM

Nasdaq : RVMD

clinical trial

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

Revolution Medicines, Inc. (Nasdaq:

RHEA-AI

neutral

08/17/23 4:05 PM

Nasdaq : RVMD

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing

RHEA-AI

neutral

08/08/23 4:05 PM

Nasdaq : RVMD

earnings

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medical Oncology) Congress 2023 and initial clinical findings for RMC-6291 at Triple Meeting Planning underway for one or more single agent pivotal trials with RMC-6236 and the first

RHEA-AI

neutral

08/03/23 4:05 PM

Nasdaq : RVMD

conferencesearnings

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2023 on Tuesday, August

RHEA-AI

neutral

08/01/23 7:00 AM

Nasdaq : RVMD

acquisition

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

R evolution Medicines Expect s to Conduct Late-Stage Development of RAS(ON) I nhibitor Drug C andidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQ Rx Board to Consider Strategic Alternatives to

RHEA-AI

neutral

06/08/23 4:05 PM

Nasdaq : RVMD

conferences

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman,

RHEA-AI

neutral

05/24/23 4:05 PM

Nasdaq : RVMD

conferences

Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will

RHEA-AI

neutral

05/08/23 4:02 PM

Nasdaq : RVMD

earnings

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RAS MULTI ), RMC-6291 (KRAS G12C ) and RMC-9805 (KRAS G12D ) – progressing on plan Appointment of chief medical officer and key leaders across late-stage development and commercial planning $909.8 million in cash, cash equivalents and

RHEA-AI

neutral

05/01/23 4:05 PM

Nasdaq : RVMD

conferencesearnings

Revolution Medicines to Report Financial Results for First Quarter 2023 After Market Close on May 8, 2023

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the first quarter 2023 on Monday, May 8,

RHEA-AI

neutral

04/13/23 4:05 PM

Nasdaq : RVMD

conferences

Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman,

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

RVMD Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitehttp://revolutionmedicines.com/
Security nameRevolution Medicines Inc
SectorManufacturing
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
CountryUS

About Revolution Medicines Inc

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.